Literature DB >> 30642609

Hard Problems Need "Soft" Science: Integrating Quality of Life into Treatment Decision Making.

Alicia K Morgans1, Charles J Ryan2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30642609      PMCID： PMC6659108          DOI： 10.1016/j.eururo.2019.01.005

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  9 in total

1.  Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer.

Authors:  Shabbir M H Alibhai; Narhari Timilshina; Sarah Duff-Canning; Henriette Breunis; Ian F Tannock; Gary Naglie; Neil E Fleshner; Murray D Krahn; Padraig Warde; Shireen Marzouk; George A Tomlinson
Journal:  Cancer       Date:  2016-09-01       Impact factor: 6.860

2.  Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer.

Authors:  Seo Hyon Baik; Fabricio Sampaio Peres Kury; Clement Joseph McDonald
Journal:  J Clin Oncol       Date:  2017-08-25       Impact factor: 44.544

3.  Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison.

Authors:  Brian D Gonzalez; Heather S L Jim; Margaret Booth-Jones; Brent J Small; Steven K Sutton; Hui-Yi Lin; Jong Y Park; Philippe E Spiess; Mayer N Fishman; Paul B Jacobsen
Journal:  J Clin Oncol       Date:  2015-05-11       Impact factor: 44.544

4.  Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.

Authors:  Yohann Loriot; Kurt Miller; Cora N Sternberg; Karim Fizazi; Johann S De Bono; Simon Chowdhury; Celestia S Higano; Sarah Noonberg; Stefan Holmstrom; Harry Mansbach; Frank G Perabo; De Phung; Cristina Ivanescu; Konstantina Skaltsa; Tomasz M Beer; Bertrand Tombal
Journal:  Lancet Oncol       Date:  2015-04-14       Impact factor: 41.316

5.  Thinking with your gonads: testosterone and cognition.

Authors:  Jeri S Janowsky
Journal:  Trends Cogn Sci       Date:  2006-01-04       Impact factor: 20.229

6.  Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.

Authors:  Daniel J Khalaf; Katherine Sunderland; Bernhard J Eigl; Christian K Kollmannsberger; Nikita Ivanov; Daygen L Finch; Conrad Oja; Joanna Vergidis; Muhammad Zulfiqar; Martin E Gleave; Kim N Chi
Journal:  Eur Urol       Date:  2018-12-24       Impact factor: 20.096

7.  Association Between Androgen Deprivation Therapy and Risk of Dementia.

Authors:  Kevin T Nead; Greg Gaskin; Cariad Chester; Samuel Swisher-McClure; Nicholas J Leeper; Nigam H Shah
Journal:  JAMA Oncol       Date:  2017-01-01       Impact factor: 31.777

8.  An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).

Authors:  Joan Carles; Angelika Pichler; Hana Korunkova; Antoaneta Tomova; Marwan Ghosn; Fadi El Karak; Joseph Makdessi; Irina Koroleva; Gisoo Barnes; Denise Bury; Ayse Özatilgan; Simon Hitier; Jana Katolicka
Journal:  BJU Int       Date:  2018-09-16       Impact factor: 5.588

9.  Genetic Variation in the Androgen Receptor and Measures of Plasma Testosterone Levels Suggest Androgen Dysfunction in Alzheimer's Disease.

Authors:  Jessie S Carr; Luke W Bonham; Alicia K Morgans; Charles J Ryan; Jennifer S Yokoyama; Ethan G Geier
Journal:  Front Neurosci       Date:  2018-08-07       Impact factor: 4.677
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.